Literature DB >> 17579348

Exploring candidate gene associations with neuropsychological performance.

Matthew B McQueen1, Lars Bertram, Christoph Lange, K D Becker, Marilyn S Albert, Rudolph E Tanzi, Deborah Blacker.   

Abstract

We hypothesize that quantitative phenotypes related to Alzheimer's disease (AD), rather than the dichotomous disease phenotype, will increase the statistical power for identifying genetic risk factors. Neuropsychological test scores, which allow for the measurement of loss of cognitive function over time, are a particularly promising option for this approach. Using data from a cohort study of prodromal AD in 365 community-recruited subjects with and without memory problems with a baseline and often one or more follow-up administrations of a detailed neuropsychological test battery, we performed both cross-sectional and longitudinal analyses using the known AD gene APOE and four other putative AD genes as predictors. APOE and a promoter polymorphism in insulin degrading enzyme (IDE_4U) showed evidence for association with cross-sectional and longitudinal changes in memory (P = 0.016-0.025) and other cognitive functions. APOE and a polymorphism in the alpha-2-macroglobulin gene (A2M18i) also showed evidence for association with cross-sectional and longitudinal changes in executive functioning (P = 0.010-0.042). In some cases, longitudinal analysis offered stronger evidence for association than could be seen cross-sectionally. These preliminary results suggest that this approach has promised the development of a quantitative phenotype related to AD, but more elaborate methods will be required to address multiple comparisons issues in the setting of correlated data. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579348     DOI: 10.1002/ajmg.b.30500

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  14 in total

1.  The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease.

Authors:  Lei Yu; Joshua M Shulman; Lori Chibnik; Sue Leurgans; Julie A Schneider; Philip L De Jager; David A Bennett
Journal:  Aging Cell       Date:  2011-12-29       Impact factor: 9.304

2.  Genetic susceptibility for Alzheimer disease neuritic plaque pathology.

Authors:  Joshua M Shulman; Kewei Chen; Brendan T Keenan; Lori B Chibnik; Adam Fleisher; Pradeep Thiyyagura; Auttawut Roontiva; Cristin McCabe; Nikolaos A Patsopoulos; Jason J Corneveaux; Lei Yu; Matthew J Huentelman; Denis A Evans; Julie A Schneider; Eric M Reiman; Philip L De Jager; David A Bennett
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

3.  Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness.

Authors:  Yu-Ling Chang; Mark W Jacobson; Christine Fennema-Notestine; Donald J Hagler; Robin G Jennings; Anders M Dale; Linda K McEvoy
Journal:  Cereb Cortex       Date:  2009-09-23       Impact factor: 5.357

Review 4.  Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Authors:  David A Bennett; Lei Yu; Philip L De Jager
Journal:  Biochem Pharmacol       Date:  2014-02-06       Impact factor: 5.858

5.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline.

Authors:  Philip L De Jager; Joshua M Shulman; Lori B Chibnik; Brendan T Keenan; Towfique Raj; Robert S Wilson; Lei Yu; Sue E Leurgans; Dong Tran; Cristin Aubin; Christopher D Anderson; Alessandro Biffi; Jason J Corneveaux; Matthew J Huentelman; Jonathan Rosand; Mark J Daly; Amanda J Myers; Eric M Reiman; David A Bennett; Denis A Evans
Journal:  Neurobiol Aging       Date:  2011-11-04       Impact factor: 4.673

Review 6.  Bringing a developmental perspective to anxiety genetics.

Authors:  Lauren M McGrath; Sydney Weill; Elise B Robinson; Rebecca Macrae; Jordan W Smoller
Journal:  Dev Psychopathol       Date:  2012-11

7.  Intermediate phenotypes identify divergent pathways to Alzheimer's disease.

Authors:  Joshua M Shulman; Lori B Chibnik; Cristin Aubin; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

8.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles.

Authors:  David A Bennett; Philip L De Jager; Sue E Leurgans; Julie A Schneider
Journal:  Neurology       Date:  2009-04-28       Impact factor: 9.910

9.  A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation.

Authors:  Olivia I Okereke; Dennis J Selkoe; Michael N Pollak; Meir J Stampfer; Frank B Hu; Susan E Hankinson; Francine Grodstein
Journal:  Int J Geriatr Psychiatry       Date:  2009-02       Impact factor: 3.485

Review 10.  APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Authors:  Susan Bookheimer; Alison Burggren
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.